300122 智飞生物
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入7,627,407-66.53%26,069,71152,917,76738,264,01130,652,416
减:营业总成本8,661,709-56.16%23,192,41843,094,35629,049,84418,466,485
    其中:营业成本5,814,019-64.94%18,931,44938,674,26225,395,50015,621,801
               财务费用223,396243.13%109,33847,21813,79821,821
               资产减值损失(125,442)374.97%(39,540)(311,994)(108,868)(92,518)
公允价值变动收益(7,777)-6,447.92%------14,400
投资收益14-84.73%------(20,026)
    其中:对联营企业和合营企业的投资收益------------
营业利润(1,512,063)-162.52%2,263,8129,373,4408,758,38011,999,973
利润总额(1,513,288)-162.75%2,253,6929,342,2938,718,00811,931,055
减:所得税费用(293,812)-192.47%235,2131,272,4251,179,0081,722,506
净利润(1,219,477)-158.24%2,018,4798,069,8687,539,00010,208,548
减:非控股权益(13,062)-52.92%--------
股东净利润(1,206,415)-156.86%2,018,4798,069,8687,539,00010,208,548

市场价值指针
每股收益 (元) *-0.504-156.86%0.8433.3623.1416.380
每股派息 (元) *----0.2000.8000.5000.600
每股净资产 (元) *12.253-6.71%12.87913.12815.14811.036
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容